Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation
Adam Bryant(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Natasha Kekre(Ottawa Hospital), Grizel Anstee(Ottawa Hospital), Harold Atkins(University of Ottawa), Nicholas Scrivens(University of Ottawa), Mitchell Sabloff(University of Ottawa), Lothar Huebsch(University of Ottawa), Dawn Maze(University Health Network), Ranjeeta Mallick(University of Ottawa), David Allan(University of Ottawa), Christopher Bredeson
Cited by 36
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
|New England Journal of Medicine|2018|598
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|442